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Prostate cancer is the second most common cancer in men and lethality is normally
associated with the consequences of metastasis rather than the primary tumor.
Therefore, targeting the molecular pathways that underlie dissemination of primary tumor
cells and the formation of metastases has a great clinical value. Bone morphogenetic
proteins (BMPs) play a critical role in tumor progression and this study focuses on the role
of BMP9- Activin receptor-Like Kinase 1 and 2 (ALK1 and ALK2) axis in prostate cancer.
In order to study the effect of BMP9 in vitro and in vivo on cancer cells and tumor growth,
we used a soluble chimeric protein consisting of the ALK1 extracellular domain (ECD)
fused to human Fc (ALK1Fc) that prevents binding of BMP9 to its cell surface receptors
and thereby blocks its ability to activate downstream signaling. ALK1Fc sequesters
BMP9 and the closely related BMP10 while preserving the activation of ALK1 and ALK2
through other ligands. We show that ALK1Fc acts in vitro to decrease BMP9-mediated
signaling and proliferation of prostate cancer cells with tumor initiating and metastatic
potential. In line with these observations, we demonstrate that ALK1Fc also reduces
tumor cell proliferation and tumor growth in vivo in an orthotopic transplantation model,
as well as in the human patient derived xenograft BM18. Furthermore, we also provide
evidence for crosstalk between BMP9 and NOTCH and find that ALK1Fc inhibits NOTCH
signaling in human prostate cancer cells and blocks the induction of the NOTCH
target Aldehyde dehydrogenase member ALDH1A1, which is a clinically relevant marker
associated with poor survival and advanced-stage prostate cancer. Our study provides
the first demonstration that ALK1Fc inhibits prostate cancer progression, identifying
BMP9 as a putative therapeutic target and ALK1Fc as a potential therapy. Altogether,
these findings support the validity of ongoing clinical development of drugs blocking
ALK1 and ALK2 receptor activity.
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INTRODUCTION
Prostate cancer is the second most common cancer in men
worldwide (Jemal et al., 2010). Currently prostate cancer,
when still in its first phase of androgen dependency, can be
successfully treated surgically. However, if the tumor becomes
androgen independent, therapy is no longer possible and lethality
is almost invariably due to the consequences of metastasis.
Therefore, understanding the molecular pathways that underlie
the emergence and spread of metastases from primary tumors is
of great biological and clinical value.
Expression of several BMPs has been examined in prostatic
tissue with benign prostatic hyperplasia (BPH), non-metastatic
andmetastatic prostatic adenocarcinoma and has been associated
with cancer aggressiveness (Ye et al., 2007; Ye and Jiang, 2016).
Among the BMPs, BMP9 is one of the most recently identified
(Song et al., 1995). Little is known about the roles of BMP9 and
its cell surface signaling receptors, ALK1 and ALK2, in prostate
cancer and particularly in androgen independent and metastatic
prostate cancer. Current research has not only attributed a
tumor-promoting role to BMP9 (Herrera et al., 2009, 2013; Li
et al., 2014) but also tumor suppressing properties (Ye et al., 2008;
Wang et al., 2011; Olsen et al., 2014) in different types of cancer,
including prostate cancer.
Previous studies have highlighted the role of ALK1, which
is predominantly expressed by endothelial cells (van Meeteren
et al., 2012), as key regulator of angiogenesis in normal tissue
and in tumors (Hawinkels et al., 2013; Bendell et al., 2014).
BMP9 and BMP10 are high affinity ligands for ALK1, while
BMP9 signals through the BMP type I receptor ALK2 (David
et al., 2007; Herrera et al., 2009; Bragdon et al., 2011). Binding
of BMP9/BMP10 to ALK1/ALK2 results in phosphorylation
and activation of downstream effectors SMAD1 and/or SMAD5
(David et al., 2007; Scharpfenecker et al., 2007; Herrera et al.,
2009). BMP9 promotes human epithelial ovarian cancer and
human immortalized ovarian surface epithelial cell proliferation
through ALK2/SMAD1/SMAD4 pathway (Herrera et al., 2009).
Similarly, BMP9 stimulates proliferation of liver cancer cells
(Herrera et al., 2013) and osteosarcoma growth (Li et al., 2014).
Several studies have highlighted the role of BMP9/ALK1
in blood vessel formation, outlining its critical involvement
in pathological and tumor angiogenesis (Urness et al., 2000;
Cunha and Pietras, 2011). Interestingly, alterations of signal
transduction pathways that are important for blood vessel
formation, such as the NOTCH pathway, have also been
associated with arterio-venous malformations (Gale et al., 2004;
Krebs et al., 2004). Recently, BMP9 and BMP10 signaling were
linked to NOTCH signaling, one of the major pathways involved
in prostate cancer development, progression and bone metastasis
(Carvalho et al., 2014; Kron et al., 2017; Zhang et al., 2017).
Expression profiling studies have shown that members of the
NOTCH pathway are characteristic of high-grade (Gleason 4+ 4
= 8)micro-dissected prostate cancer cells compared to low-grade
(Gleason 3 + 3 = 6) (Ross et al., 2011). Moreover, inhibition
of NOTCH1 reduces prostate cancer cell growth, migration
and invasion (Wang et al., 2010). Interestingly, the NOTCH
signaling indirectly activates the enzymatic activity of ALDH1A1,
a well-known marker of prostate cancer stem cells (Ginestier
et al., 2007; Li et al., 2010; Le Magnen et al., 2013; Zhao et al.,
2014), which are thought to be responsible for tumor recurrence,
metastasis and cancer related death (Moltzahn and Thalmann,
2013).
In order to understand the role of BMP9 in prostate cancer
progression, we employed the soluble chimeric protein ALK1Fc
(ACE-041) (Seehra et al., 2009) which binds BMP9 and BMP10
with high affinity and blocks their signaling via ALK1 and ALK2
receptors by acting as a ligand trap (Cunha et al., 2010; Mitchell
et al., 2010). Phase I clinical trials have been completed using
ALK1Fc as anti-angiogenesis therapy in myeloma (clinicaltrials.
gov identifier NCT00996957). Here we show that ALK1Fc
reduces BMP9 signaling and decreases proliferation of highly
metastatic human prostate cancer cells in vitro. We further
demonstrate that ALK1Fc impairs tumor angiogenesis, affects
tumor cell proliferation and reduces tumor growth in vivo. Taken
together these data suggest BMP9 as a possible therapeutic target
in prostate cancer and provide a new rationale for ongoing
clinical development of drugs blocking BMP9 signaling via ALK1
and ALK2.
MATERIALS AND METHODS
Cell Line and Culture Conditions
The human osteotropic prostate cancer cell line PC-3M-Pro4-
Luc2 (Kroon et al., 2014; Zoni et al., 2015, 2017) was maintained
in DMEM supplemented with 10% FCII, 0.8mg/ml Neomycin
(Santacruz, Dallas, USA) and 1% Penicillin-Streptomycin (Life
Technologies, Carlsbad, USA).
Recombinant Proteins and Chemical
Inhibitors
ALK1Fc (de Vinuesa et al., 2016) is a fusion protein comprised
of the extracellular domain (ECD) of human ALK1 fused to
the Fc region of IgG and was obtained from Acceleron Pharma,
Cambridge, USA. As a control we used either the Fc domain of
IgG1 (MOPC-21; Bio Express,West LebanonNH) or normal goat
IgG from R&D System.
Recombinant human BMP9 was obtained from R&D System,
whereas the chemical inhibitor LDN193189 was purchased
from Axon Medchem. The final concentration for the in vitro
experiments was 1 nM for BMP9 and 120 nM for LDN193189.
Lentiviral-Mediated RNA Interference of
NOTCH1
shRNAi for NOTCH1 (TRC000000350253, TRC000000350330,
TRC0000003361, TRC0000003360) were obtained from Sigma
MISSION library and used for lentiviral vector production
and transduction as described previously (Zoni et al., 2017).
Scramble shRNA (NT; SHC002, Sigma) was used as control. The
transduced cells underwent puromycin selection and used for
further experiments as described below. The experiments were
carried out in accordance with standard biosecurity procedures.
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Luciferase Reporter Assays and
Constructs
PC-3MPro4 cells were seeded at density of 50,000 cells in
500 µL medium in a 24-well plate. Transient transfection of
reporter constructs was performed with Lipofectamine2000 (Life
Technologies) according to the manufacturer’s protocol. For
each well, 100 ng of NICD-ff-luciferase, 10 ng CAGGS-Renilla
luciferase, 100 ng BRE renilla (Korchynskyi and ten Dijke, 2002)
and 100 ng BREluc/well were transfected. After 24 h, medium
was replaced and cells were treated with BMP9 for 24 h. The
Firefly luciferase and Renilla luciferase levels in the lysates
were measured using Dual Luciferase Assay (Promega, Madison,
USA).
RNA Isolation and Real-Time Q-PCR
Total RNA was isolated from PC-3M-Pro4-Luc2 cells with Trizol
Reagent (Invitrogen, Waltham, USA) and cDNAwas synthesized
by reverse transcription (Promega, Madison, USA) according
to the manufacturer’s protocol. qRT-PCR was performed with
Biorad CFX96 system (Biorad, Veenendaal, The Netherlands).
Gene expression was normalized to GAPDH or β-actin. Total
RNA from frozen section (5µm) was isolated with Qiagen
Mini Isolation kit (Venlo, The Netherlands) according to
the manufacturer’s protocol. Primer sequences are listed in
Supplementary Table I.
MTS Assay
Cells were seeded at density of 2,000 cells/well in low serum
condition (0.3% FCII), treated with ALK1Fc or Control-Fc (CFc)
(10µg/ml, Acceleron, USA) and allowed to grow for 24, 48, 72,
and 96 h. After incubation, 20 µl of 3-(4,5 dimethylthiazol- 2-
yl)- 5 -(3 -carboxymethoxyphenyl)- 2 -(4 -sulfophenyl)- 2 H-
tetrazolium (MTS) was added and mitochondrial activity was
measured after 2 h incubation at 37◦C. MTS absorbance values
are positively proportional to total number ofmetabolically active
cells providing an indirect correlation with cell proliferation rate
(CellTiter96 Aqueous Non-radioactive Cell proliferation assay,
Promega) (Berridge et al., 2005).
Animals
Male 6–8 week-old athymic nude (Balb/c nu/nu) or CB17
SCID mice, purchased from Charles River (L’Arbresle, France),
were used in all in vivo experiments. Mice were housed in
individual ventilated cages under sterile condition, and sterile
food and water were provided ad libitum. Animal experiments
were approved by the local committee for animal health ethics
and research of Leiden University (DEC #11246) and Canton of
Bern, Switzerland (Permit Number: BE55/16), and carried out
in accordance with European Communities Council Directive
86/609/EEC and Swiss Guidelines for the Care and Use of
Laboratory Animals.
Orthotopic Prostate Transplantation and
ALK1Fc Treatment
25,000 PC-3M-Pro4-Luc2 cells (10µl final volume) were injected
in the dorsal prostate lobe of anesthetized male nude mice.
In brief: After anesthetizing the mice with isoflurane, each
mouse was placed on its back and a small incision was
made along the lower midline of the peritoneum for about 1
cm. The prostate dorsal lobes were exteriorized and stabilized
gently. A 30-gauge needle attached to a 1-cc syringe was
inserted into the right dorsal lobe of the prostate. 10 µl of
the cell suspension was slowly injected. A well-localized bleb
indicates a successful injection. After retracting the needle, a
Q-tip was placed over the injection site for about 1min to
prevent bleeding and spillage of material. The prostate was
then returned to the peritoneum and the abdominal wall and
skin layer was sutured. After establishment of the primary
tumor, at 10 days after the orthotopic transplantation, mice
were intraperitoneally injected with Control-Fc (CFc) or ALK1Fc
compounds (10mg/kg) twice per week. Administration of
compounds was performed for 4 weeks. After the experimental
periods, mice were injected with hypoxia probe (6mg/kg,
Burlington, Massachusetts, USA) and lectin-Tomato (1mg/kg,
Vector Laboratories, USA) intravenously prior to perfusion
and sacrificed according to our mouse protocol. Tumors were
dissected and processed for further histomorphological analysis
as described below.
Subcutaneously BM18 Transplantation and
ALK1Fc Treatment
BM18 xenografts were transplanted subcutaneously in CB17
SCIDmice anesthetized with a cocktail of medetomidin (1 mg/kg
body weight), midazolam (10mg/kg) and fentanyl (0.1mg/kg)
(Schwaninger et al., 2007). After 1 week, the animals were
intraperitoneally injected with ALK1Fc or IgG at the dose of
10 mg/kg once a week, for 5 weeks. Every week the tumors
were measured with the caliper and finally dissected and fixed
in 4% paraformaldehyde (PFA) for paraffin embedding and
hematoxylin and eosin staining.
Whole Body Bioluminescent Imaging (BLI)
Tumor growth from orthotopic injection was monitored
weekly by whole body bioluminescent imaging (BLI) using
an intensified-charge-coupled device (I-CCD) video camera of
the in vivo Imaging System (IVIS100, Xenogen/Perkin Elmer,
Alameda, CA, USA) as described previously (Buijs et al., 2007;
van den Hoogen et al., 2010). In the orthotopic transplantation
experiment the newer IVIS Lumina II (Xenogen/Perkin Elmer,
Alameda, CA, USA) was used for BLI measurements. Mice were
anesthetized using isoflurane and injected intraperitoneally with
2mgD-luciferin (Per bio Science Nederland B.V., Etten-Leur, the
Netherlands). Analyses for each metastatic site were performed
after definition of the region of interest and quantified with
Living Image 4.2 (Caliper Life Sciences, Teralfene, Belgium).
Values are expressed as relative light units (RLU) in photons/s.
Immunofluorescence
Immunofluorescence staining was performed on 5-µm paraffin
embedded sections. For antigen retrieval, sections were boiled
in antigen unmasking solution (Vector Labs, Peterborough, UK)
and stained with anti- pH3 (Millipore), cleaved CASP3 (Cell
Signaling), CD31 (Sigma) or ALDH1A1 (Abcam) antibodies.
Sections were blocked with 1% bovine serum albumin (BSA)-
PBS-0.1% v/v Tween-20 and incubated with primary antibodies
diluted in the blocking solution, overnight at 4◦C. Sections were
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then incubated with secondary antibodies labeled with Alexa
Fluor 488, 555, or 647 (Invitrogen/Molecular Probes, Waltham,
USA) at 1:250 in PBS-0.1% Tween-20. Nuclei were visualized
by TO-PRO3 (Invitrogen/Molecular Probes, 1:1000 diluted in
PBS-0.1% Tween-20) (Karkampouna et al., 2014).
Western Immunoblotting
Cell lysates were prepared using RIPA buffer (Thermo Scientific)
and protein concentrations were quantified according to
manufacturer’s protocol (Thermo Scientific). Proteins (20 µg per
sample) were separated by 15% SDS-PAGE followed by transfer
to a blotting membrane. The membrane was blocked with 5%
Milk, dissolved in PBS-Tween, for 1 h at room temperature.
The membrane was incubated with 1:1,000 primary antibody
(anti-NOTCH1, Cell Signaling, catalog number 3608) at 4◦C
overnight. Subsequently, the membrane was incubated with
1:10,000 secondary horseradish peroxidase (HRP) antibody. All
antibodies were dissolved in PBS-Tween. Chemiluminescence
was used to visualize the bands.
Clonogenic Assay
Clonogenic assay was performed in 6 well plate. 100 cells were
seeded in 2mL of medium and incubated at 37◦C in presence of
5% CO2 for 2 weeks. Plates were washed with PBS and cells fixed
for 5min with a solution of 4% PFA. Colonies were stained with
0.1% crystal violet (Sigma-Aldrich, The Netherlands) and plates
were imaged before processing the data with ImageJ software
(Franken et al., 2006; Rafehi et al., 2011; Guzman et al., 2014).
Prostate Cancer Dataset Analysis
The Taylor MSKCC prostate dataset was queried for BMP9
and ALK1 expression in prostate cancer patients through
the online biomarker validation tool SurvExpress (http://
bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp). The
data are censored as “recurrence month,” and the risk groups
are defined estimating a prognostic index by the Cox model
algorithm (Aguirre-Gamboa et al., 2013).
R2: Genomics Analysis and Visualization Platform (http://r2.
amc.nl) was used to investigate the ALK2, JAG1 and NOTCH1
expression in benign (n= 48) vs. tumor (n= 47) tissues using the
GEO accession number GSE29079 dataset (Borno et al., 2012).
Statistical Analysis
Statistical analysis was performed with GraphPad Prism 6.0
(GraphPad software) using t-test or ANOVA for comparison
between more groups. Data is presented as mean ± SEM. P-
values < 0.05 were considered to be statistically significant (∗P
< 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).
RESULTS
High BMP9 and ALK1 Correlate with
Recurrence in Prostate Cancer Patients
The role of BMP9 in cancer development and progression is
still controversial. We analyzed a Taylor MSKCC Prostate dataset
(GSE21032) through the online tool SurvExpress to assess how
the expression of BMP9 and ALK1 is related with recurrence
in prostate cancer. We found that the group of patients with
high expression of BMP9 and ALK1 has higher probability to
encounter biochemical recurrence than the group with lower
levels of BMP9 and ALK1 (Figures 1A,B top). The SurvExpress
tool also defines “high-” and “low-” risk group of patients based
on the risk prognosis calculated as described in the Material and
Methods. According to that definition, we also found that the
high-risk group of patients had higher expression of BMP9 and
ALK1 than lower risk patients (Figures 1A,B bottom). Therefore,
we explored whether inhibition of BMP9 signaling in mouse
models of prostate cancer interferes with tumor growth.
ALK1Fc Reduces Primary Prostate Tumor
Burden in Vivo
To investigate the role of BMP9 in prostate cancer progression,
the BMP9 ligand trap ALK1Fc was administered in an orthotopic
mouse model of prostate cancer. Primary prostate tumor growth
was induced by intra-prostatic inoculation of human prostate
cancer PC-3M-Pro4-Luc2 cells in Balb/c nude mice and tumor
progression was followed by bioluminescence imaging (BLI)
(Kroon et al., 2014) (Figure 2A). Based on the BLI signal the
mice were randomized in two treatment groups: ALK1Fc or
control (C) Fc (n = 15 per group). The recombinant proteins
were injected twice weekly and tumor imaging and body weights
were monitored weekly for 5 weeks (Supplementary Figure 1).
Tumor burdenwas quantitatively assessed for each animal during
the course of treatment. The group of animals that received
ALK1Fc exhibited smaller tumor size compared to the animals
that received CFc based on bioluminescence quantification
(Figure 2B, p< 0.01).
ALK1Fc Reduces Cell Proliferation in the
Primary Prostate Tumor
The degree of tumor angiogenesis is critical for progressive tumor
growth beyond a few mm3 in size. Intravital lectin perfusion
was used to map the perfused elements of the tumor vasculature
in mice. Fluorescent-conjugated lectin (lectin-Tomato) was
visualized in tumor tissue sections and quantified. We observed
a trend in decreased vascular density, indicated by the overall
lectin presence, in the tumors treated with ALK1Fc compared
to the CFc group (Supplementary Figures 2A,B). We evaluated
the presence of endothelial cells in tumor sections by CD31
immunofluorescence. A trend of decreased CD31 expression was
also observed after treatment with ALK1Fc suggesting fewer
endothelial cells and vessels (Supplementary Figures 2C,D).
Hypoxia is an important component of angiogenesis and critical
for tumor formation. A hypoxia-induced probe was injected
in tumor bearing mice just prior to sacrifice and the hypoxic
areas within the tumors were visualized after tumor resection
(Figure 3A; left panels). Although hypoxic areas were found
in both treatment groups, the overall amount of hypoxia
seemed to be higher in ALK1Fc-treated mice relative to the
CFc-treated mice (Figure 3A; right graph, p = 0.050). We
assessed the presence of cell proliferation and cell death in
these tumors by immunofluorescence for the mitosis marker
phosphorylated histone 3 (PH3) and the apoptosis marker
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FIGURE 1 | BMP9 and ALK1 correlate with poor patient prognosis. (A,B) Top panels: Kaplan-Meier survival curves of censored Cox analysis in Taylor-MSKCC
prostate database stratified by maximized BMP9 and ALK1 expression risk groups. Subjects with a higher expression display earlier biochemical recurrence than
subjects with a lower risk (Bovelstad and Borgan, 2011). Red, high expression; Green, low expression. CI, Concordance Index; HR, Risk Group Hazard Ratio. Bottom
panels: BMP9 and ALK1 expression levels stratified by risk groups. Red, high Risk; Green, low risk.
cleaved caspase 3 (CASP3), respectively. Dividing PH3 positive
cells are predominantly located in normoxic areas (Figure 3A;
left panel). Quantification of immunofluorescence signal shows
that the number of dividing cells is lower in the ALK1Fc-treated
animals (Figure 3A; right graph p< 0.05). Detection of apoptotic
cells (Caspase-3 positive) is higher in the ALK1Fc-treated tumors
(Figure 3A; right graph p < 0.05) and occurs mostly, but not
exclusively, in hypoxic areas (Figure 3A; left panel), suggesting
a correlation between the hypoxia and tumor cell death.
ALK1Fc Decreases Proliferation of Human
Prostate Cancer Cells in Vitro
To investigate how ALK1Fc can decrease tumor growth, we
studied the effect of ALK1Fc on prostate cancer cells. We
measured the mRNA levels of the BMP9 type I receptors ALK1
and ALK2 in the PC-3M-Pro4-Luc2 (Kroon et al., 2014) human
prostate cancer cell line and tested their response to BMP9.
Consistent with a previous report in highly metastatic PC-
3 and PC-3M prostate cancer cells (Craft et al., 2007), qRT-
PCR analysis in osteotropic PC-3M-Pro4-Luc2 cells revealed
undetectable levels of ALK1 but measurable levels of ALK2
(Supplementary Figure 3A). Treatment with BMP9 showed a
dose-dependent induction of BRE-Renilla luciferase (luc) activity
in PC-3M-Pro4 cells (p-value = 0.005 and 0.05 with 0.5 nM
and 1 nM BMP9, respectively) indicative of conserved and active
canonical Smad signaling machinery (Supplementary Figure 3B).
We subsequently tested the combined effect of treating cells
with 1 nM BMP9 and either ALK1Fc or CFc on BRE reporter
assay and found that treatment with ALK1Fc (10µg/mL)
completely abolished BMP9 signaling (Supplementary Figure
3C; BMP9+ALK1Fc) as evidenced by BRE-luc activity levels
similar to that of cells without BMP9 treatment (Untreated).
Treatment with BMP9+CFc (10µg/mL) led to induction of BRE-
luc activity that was similar to the level of BMP9 treatment alone
(Supplementary Figure 3C; p-value< 0.05). Taken together, these
results indicate that ALK1Fc blocks BMP9 signaling via ALK2 in
PC-3MPro4 cells.
Moreover, ALK1Fc treatment, but not CFc, strongly reduced
BMP9-induced cell proliferation in PC-3M-Pro4-Luc2 (p< 0.001
at day 4 comparing vehicle vs. BMP9 or ALK1Fc treatment,
respectively; Figure 3B). This effect appeared to be specific
(Supplementary Figure 3D) since treatment of PC-3M-Pro4-
Luc2 cells with BMP9 in combination with an ALK2 small
molecule kinase inhibitor (LDN193189, LDN) (Cuny et al.,
2008; Shi et al., 2011) similarly resulted in the complete loss
of BMP9-induced cell proliferation (Figure 3C). LDN treatment
also blocked BMP9 stimulation of the BRE-luc reporter in PC-
3M-Pro4-Luc2 cells (Supplementary Figure 3E). Together, these
data indicate that ALK1Fc strongly reduces BMP9- induced
proliferation in human prostate cancer cells.
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FIGURE 2 | ALK1FC reduces primary prostate tumor burden. (A) PC-3M-Pro4-Luc2 cells were orthotopically injected in the dorsal lobe of prostate glands of nude
mice (n = 15 per group). Detection of primary tumor burden was observed at 2 weeks after injection, with the time point designated as “week 1” at the start of
treatment with ALK1Fc or CFc. Representative examples of bioluminescent images of tumor burden at the start of treatment with ALK1Fc/CFc (week 1) and at the
end point (week 5). (B) Quantification of bioluminescent signal (photons/sec) in mice treated with either CFc (n = 14) or ALK1Fc (n = 15) for 5 weeks. Error bars
indicate ± SEM. **P-value < 0.01.
ALK1Fc Inhibits ALDH1A1 Expression in
Vivo and Interferes with NOTCH Signaling
Given its ability to reduce primary tumor burden and block
BMP9-induced tumor cell proliferation in vitro and in vivo,
we assessed the effects of ALK1Fc on the relative expression
of ALDH1A1, a marker previously associated with cancer
stem cell-like properties and poor patient prognosis (Li et al.,
2010; Le Magnen et al., 2013). Treatment of prostate tumor
bearing mice with ALK1Fc affected the number of ALDH1A1
positive cells in the prostate tumor tissues both at the protein
(Figure 4A) and mRNA levels (Figure 4B). In vitro stimulation
with BMP9 of the same cell line used to induce tumors in
the xenograft mouse model confirmed that treatment with
BMP9 or BMP9+CFc upregulates ALDH1A1 expression while
BMP9+ALK1Fc treatment does not have any effect (Figure 4C).
We tested the effects of BMP9 treatment on the colony
forming capacity of PC-3M-Pro4-Luc2 cells (Figure 4D) and
found that it alters cell proliferation and strongly increasing
the size of the colonies (Figure 4E, p < 0.05). However, BMP9
showed no effect on colony formation ability of PC-3M-Pro4-
Luc2 since the total number of colonies formed with or without
BMP9 treatment is similar (Figure 4F).
ALDH1A1 is known to be regulated by NOTCH signaling
(Ginestier et al., 2007; Le Magnen et al., 2013; Zhao et al., 2014)
and NOTCH1 plays a prominent role in prostate cancer cell
proliferation and migration (Shou et al., 2001; Zhang et al., 2006;
Leong and Gao, 2008; Bin Hafeez et al., 2009; Wang et al., 2010).
Larrivee et al. have shown that ALK1 and NOTCH converge
on common downstream pathways and that BMP9 treatment is
sufficient to upregulate expression of theNOTCHpathway ligand
JAG1 in HUVEC non-transformed cells (Larrivee et al., 2012).
To assess the clinical relevance of crosstalk between
BMP9/ALK2 signaling and NOTCH pathway activation in
human prostate cancer, we performed bioinformatics analysis in
48 benign prostate tumors and 47 malignant prostate tumors
(Borno et al., 2012) using R2 data mining platform (source: GEO
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FIGURE 3 | ALK1Fc increases hypoxia and apoptosis and decreases cell proliferation in vivo. (A) Left panels: Representative images of hypoxia immunofluorescence
staining (red) in primary prostate tumor samples after 5 weeks of treatment with either ALK1Fc or CFc. Hypoxia probe was injected prior to sacrifice and was detected
by a specific fluorescent antibody. Immunofluorescence images for colocalization of apoptotic or proliferating cells in hypoxic/normoxic area within the prostate tumor
area in ALK1Fc and CFc treated animals. pH3: PhosphoHistone 3 proliferation marker (green); cleaved caspase 3 apoptosis marker (green); Hypoxic probe-antibody:
hypoxic area (red); TOPRO: nuclear dye (blue). Right graphs: Quantification of hypoxia, pH3 and cl.CASP3 positive area in all tumor samples of each group (n = 6 for
CFc, n = 7 for ALK1Fc). (B) MTS assay (24, 48, 72, 96 h) was performed in PC-3M-Pro4-Luc2 cells stimulated with recombinant BMP9 (1 nM), BMP9 (1 nM) +
ALK1Fc (10µg/ml), or BMP9 (1 nM) + CFc (10µg/ml). Accumulation of MTS was measured based on absorbance at 490 nm. Values are normalized to the basal
measurements at 24 h after cell seeding and treatments. Graph represents values for three independent experiments (n = 3). Error bars indicate ± SEM. **P-value <
0.01 BMP9 vs. Untreated and ***P-value < 0.001 BMP9+CFc vs. Untreated. (C) MTS assay (24, 48, 72, and 96 h) performed in PC-3M-Pro4-Luc2 cells seeded at
low density in 96-well plates and treated with BMP9 (1 nM), LDN (BMP type I receptor inhibitor LDN193189, 120 nM) or LDN+BMP9. (n = 2). Values are normalized to
the basal measurements at the time of cell seeding and treatments. Error bars indicate SEM. **P-value < 0.01 BMP9 vs. LDN and BMP9 vs. LDN+-BMP9; ***P-value
< 0.001 BMP9 vs. Untreated; $$$BMP9 vs. LDN; ###BMP9 vs. LDN+BMP9; *P-value < 0.05.
ID: GSE29079). Transcript levels of ALK2, the NOTCH ligand
JAG1, and NOTCH1 were significantly higher in the malignant
tumor group compared to the benign group (Figures 5A–C).
We targeted the expression of NOTCH1 in PC-3M-Pro4-
Luc2 using a specific shRNA (shNOTCH1) and assessed
resulting NOTCH1 levels by western blot and reporter assay
(Supplementary Figures 4A,B). NOTCH1 knockdown led to a
decreased proliferation rate compared to cells transduced with
non-targeting shRNA lentivirus (p < 0.05 at 48 h and at 72 h)
(Figure 5D). Notably, we observed that that shNOTCH1-cells
display decreased levels of JAG1 mRNA (Supplementary Figure
4C) relative to control cells and that stimulation of shNOTCH1-
cells with BMP9 rescued their proliferation rate (Figure 5D). To
verify the effect of BMP9 on NOTCH signaling activation in our
cancer model, we used qRT-PCR to quantify the expression of
JAG1 after BMP9 stimulation in presence of ALK1Fc or CFc.
Our transcriptional analysis showed that BMP9 and BMP9+CFc
induce mRNA expression of JAG1 and that ALK1Fc treatment
reduces this induction (Figure 5E). These data reinforce the
hypothesis that the BMP9/ALK2 pathway can drive activation of
NOTCH signaling linking two pathways that are associated with
tumor progression in prostate cancer.
ALK1Fc Reduces Tumor Burden in the
BM18 Patient Derived Xenograft Model
While cell lines and mouse models are of great help in addressing
biological questions, there is an increased need for personalized
treatments and precision medicine based on screening of
human material is becoming increasingly important. Therefore,
we tested the antitumoral effect of ALK1Fc on the human
patient derived xenograft (PDX) BM18. This PDX was derived
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FIGURE 4 | ALK1Fc treatment reduces ALDH1A1 expression. (A) Representative images of ALDH1A1 immunofluorescence in prostate tumor samples from ALK1Fc
and CFc treated animals. ALDH1A1: red; TOPRO: blue. (B) Quantification of ALDH1A1 mRNA by Q-PCR in tumor samples of each group (n = 5 for CFc, n = 5 for
ALK1Fc). (C) Expression of ALDH1A1 in PC-3M-Pro4-Luc2 cells. Relative mRNA expression was measured by Q-PCR from cDNA obtained from PC-3M-Pro4-Luc2
cells treated with BMP9, BMP9+ALK1Fc, BMP9+CFc, for 48, 72, and 96 h. Values are normalized to β-actin expression. Error bars are ± SEM (n = 3). $P-value <
0.05; $$P-value < 0.01. (D) Clonogenic assay of PC-3M-Pro4-Luc2 cells. Low-density cultures (100 cells per well of 6 well plate) were stimulated with BMP9, CFc,
ALK1Fc, BMP9+CFc, BMP9+ALK1Fc. Colony formation was assessed after 10 days by crystal violet staining. Representative images are shown. (E,F) Quantification
of surface covered by crystal violet positive colonies (colony area) and colony number. Graph shows percentage of positive surface normalized per condition (average
of three independent experiments). *P-value < 0.05. Error bars indicate SEM.
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FIGURE 5 | Effect of BMP9 and ALK1Fc on NOTCH signaling pathway. (A–C) Bioinformatic analysis of AMC OncoGenomics database (Sueltman transcript
comparison) showing mRNA expression of ALK2 (A) JAG1 (B) and NOTCH1 (C) in prostate tissues among benign prostate tissues (n = 48) vs. tumor tissues (n =
47). Values are expressed as 2log ratio tumor/benign. ***P-value < 0.001. (D) MTS assay (24, 48, 72, and 96 h) in PC-3M-Pro4-Luc2 cells transduced with short
hairpin RNA against NOTCH1 (shNOTCH1) lentiviral vector or non-targeting (NT) shRNA vector (mock) and plated at low density. BMP9 (1 nM) was added once at cell
seeding (t = 0). MTS absorbance was measured and values are normalized to the basal measurements t = 0 after cell seeding and treatments. Graph represents
values for three independent experiments (n = 3). Error bars indicate SEM. *P-value < 0.05. (E) Expression of JAG1 in PC-3M-Pro4-Luc2 cells. Relative mRNA
expression was measured by Q-PCR from cDNA obtained from PC-3M-Pro4-Luc2 cells treated with BMP9, ALK1Fc, CFc, BMP9+ALK1Fc or BMP9+CFc for 96 h.
Values are normalized to β-actin expression. Error bars are ± SEM (n = 3). **P-value < 0.01.
from prostate cancer tissue harvested from femoral metastasis
(McCulloch et al., 2005) and it is vitally maintained through
serial passage in immunocompromised mice (Germann et al.,
2012). We transplanted BM18 cells subcutaneously in severe
combined immunodeficiency SCID mice and after 1 week the
animals were treated with 10 mg/kg ALK1Fc or an IgG control
once a week for an additional 5 weeks. Body weights of the
mice were monitored weekly (Supplementary Figure 5) and
the tumor growth was assessed by caliper measurement. We
observed significant reduction in tumor burden upon ALK1Fc
but not IgG administration (Figures 6A,B) and assessed the
prostate epithelial phenotype of the tumors by the hematoxylin
eosin (H&E) staining (Figure 6C).
DISCUSSION
In this study, we found that BMP9 has a tumor-promoting
effect on human prostate cancer cells both in vitro and in vivo.
We demonstrate that blocking BMP9 signaling with ALK1Fc
efficiently diminishes prostate cancer cell proliferation and
substantially attenuates tumor growth in both an orthotopic
model of human prostate cancer and a prostate cancer derived
PDX.
BMP9 was first identified in the liver (Song et al., 1995)
and active forms are present in serum (Herrera et al., 2009).
BMP9 is a ligand for ALK1 in endothelial cells (van Meeteren
et al., 2012) and exerts stimulatory or inhibitory effects on
endothelial cell growth and migration depending on the cellular
context (David et al., 2007; Suzuki et al., 2010; Liao et al.,
2017). Aberrant regulation of transforming growth factor-β
(TGF-β) and BMP signaling often results in cancer progression
(Siegel and Massague, 2003; Massagué, 2008). In particular, BMP
ligands, such as BMP9 as well as BMP type I receptors (e.g.,
ALK1 and ALK2) have been associated with tumor angiogenesis
and cancer progression. BMP9 signals through ALK2 in non-
endothelial cells including those in ovarian epithelium, where
it has been shown to promote proliferation of ovarian cancer
cells (Herrera et al., 2009). Similarly, in hepatocellular carcinoma
BMP9 has been reported to act as a factor that promotes cell
proliferation and survival (Herrera et al., 2013). More recently,
the BMP9/ALK2 axis has also been involved in erythroblast
cancer cells proliferation (Kim et al., 2017). By contrast, studies
have also highlighted the role of BMP9 in reducing breast cancer
cell growth and metastasis (Wang et al., 2011, 2017; Ren et al.,
2014a,b). Overall, the role of BMP9 and ALKs in promoting or
suppressing different cancer types remains controversial and the
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FIGURE 6 | ALK1Fc reduces tumor burden in human prostate cancer xenograft BM18. Human PDX BM18 were transplanted subcutaneously in CB17 SCID mice
(two tumors/animal) and treated either with ALK1Fc (n = 3) or IgG (n = 2). (A) Quantification of tumor burden by caliper measurement. Tumors treated with ALK1Fc n
= 6; tumors treated with IgG n = 4. ***P < 0.01. Error bars indicate ± SD. (B) Representative images of BM18 tumor size after 5 weeks of treatment. (C) HE staining
of BM18 after 5 weeks of treatment with ALK1Fc or IgG, left and right respectively.
effect of BMP9 on tumor promotion vs. tumor suppression is
likely to be context and cancer-type specific. This provided the
rationale for us to elucidate the role of BMP9 in prostate cancer,
for which no information is available to our knowledge.
In our search of publicly available databases of human
prostate cancer specimens we found that BMP9 was expressed
at significantly higher levels in high risk prostate cancer patients
compared to the low risk group and that ALK2 was significantly
upregulated in malignant vs. benign tissue samples. These data
are consistent with our model in which the tumor-promoting
effects of BMP9 are mediated by ALK2. Additionally, microarray
analysis of data from mouse prostate intraepithelial neoplasia
(PIN) vs. invasive cancer in a multistage model of prostate
carcinogenesis showed up regulation of ALK2 and BMP9 at the
invasive stage in the stromal compartment (Bacac et al., 2006).
These data, together with the anti-tumorigenic effect of ALK1Fc
documented here, suggest a tumor-promoting role of BMP9
during prostate cancer progression.
Our in vitro findings strengthen the afore-mentioned
expression data and suggest that BMP9 increases proliferation
of human prostate cancer cells. Moreover, our studies with
the ALK2 inhibitor LDN193189 support the notion that ALK2
is critically involved in mediating BMP9-induced proliferation
in PC-3M-Pro4-Luc2 cells. As depicted in the Results and
Supplementary Data sections, treatment with ALK1Fc or
LDN193189 alone did not affect proliferation of human prostate
cancer cells suggesting a paracrine effect of stroma-derived BMP9
on tumor cells.
We also used an orthotopic model of prostate cancer to
demonstrate that ALK1Fc reduces prostate tumor burden and
vascular density compared to the controls. Lectin distribution
appeared to be less diffuse in ALK1Fc treated animals, suggesting
an effect on vessel maintenance rather than angiogenesis.
Strikingly, ALK1Fc treatment of tumor-bearing animals resulted
in highly hypoxic tumors with a trend in decreased number of
CD31+ tumor capillaries suggesting that ALK1Fc may block
BMP9-induced neovascularization.
As expected, areas of tumor proliferation and apoptosis were
found to be mutually exclusive in their distribution. Apoptotic
regions overlapped with hypoxic areas, suggesting that blockade
of BMP9 by ALK1Fc might have an effect on proliferation and
apoptosis of human prostate cancer cells in addition to targeting
vessel maintenance (Mitchell et al., 2010).
SMAD1 and SMAD5 are downstream intracellular effectors
of BMP9 signaling and can directly interact with the JAG1
promoter and induce transcription of the NOTCH ligand JAG1
(Larrivee et al., 2012) following BMP9 treatment (Morikawa
et al., 2011). Transcriptional analysis revealed that ALK1Fc
systemically blocks the induction of JAG1 mRNA in the
presence of BMP9 (Morikawa et al., 2011) supporting our
hypothesis that the crosstalk between BMP9 and NOTCH
signaling may have clinical implications in prostate cancer.
Indeed, in silico analysis of a previously published dataset
of human prostate cancer specimens confirms that both
NOTCH1 and JAG1 are upregulated at the tumor stage
(Borno et al., 2012). In particular, NOTCH signaling seems to
promote epithelial-mesenchymal transition in prostate cancer
cells (Zhang et al., 2017). Moreover, recent publication shows
how NOTCH pathway inhibition antagonizes the growth
and invasion of TMPERSS2-ERG positive prostate cancer
cells (ERG overexpressing prostate tumor) (Kron et al.,
2017) suggesting an important role of the cascade in tumor
growth.
Interestingly, NOTCH activates ALDH1A1, an established
marker for highly tumorigenic prostate cancer stem cell-like
cells (Ginestier et al., 2007; Le Magnen et al., 2013; Zhao et al.,
2014; Harris and Kerr, 2017). The ALDH1A1 subpopulation
contributes to both tumor initiation and progression and when
highly expressed in advanced-stage cancers correlates with poor
survival in hormone-naïve patients (Le Magnen et al., 2013).
Notably, we show here that ALK1Fc-treated tumors showed
significant reduction of ALDH1A1. Taken together, these data
suggest that ALK1Fc might potentially interfere with NOTCH
signaling in the regulation of ALDH1A1.
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Our conclusion that BMP9 promotes aggressive prostate
cancer growth was further supported by our demonstration
that administration of ALK1Fc inhibited the growth of BM18
PDX, an androgen-dependent bone metastatic prostate tumor.
Importantly, these data confirm the ability of ALK1Fc to treat a
tumor derived from human patient and open new perspectives in
the clinical application of this ligand trap for the cure of prostate
cancer.
Our findings provide novel information on the role of BMP9
in human prostate cancer and suggest the promising use of BMP9
targeting molecules for the treatment of tumor and supportive
microenvironment in prostate cancer patients.
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